After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
European regulators have delayed PTC Therapeutics' request for permanent approval of its Duchenne muscular dystrophy drug Translarna.
Sarepta Therapeutics (SRPT) met analysts’ 2016 second quarter earnings expectations, recording a net loss for the quarter.
Santhera's timetable for approval in the U.S. of its Duchenne drug Raxone is pushed back to 2020 after the FDA said a second, successful phase III study will be required.
Trade-Ideas LLC identified Sarepta Therapeutics (SRPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.